Based in Scandinavia, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets are in late-stage clinical trials for the symptomatic treatment of PD: mesdopetam (D3 antagonist) and pirepemat (PFC enhancer).
IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD) and other central nervous system disorders. IRLAB’s proprietary ISP research platform is at the heart of its discovery engine and has been validated by the progress of its two lead assets, mesdopetam and pirepemat, which have novel mechanisms of action. Pirepemat is an oral prefrontal cortex enhancer currently in development for the treatment of impaired balance and falls in PD; a global Phase IIb study is expected to start shortly. Mesdopetam, an oral D3 antagonist, is currently in a global Phase IIb/III study for levodopa-induced dyskinesias and top-line data are expected in H222. A global licensing deal (worth up to $363m) for mesdopetam puts all future clinical development and commercialisation in the hands of partner Ipsen, enabling IRLAB to focus on its preclinical pipeline which consists of IRL942, IRL 757 and compounds from its P003 programme. IRLAB is well funded in the medium term.
PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.